Acquired Immunodeficiency Syndrome, HIV
Conditions
Keywords
antiretroviral therapy, education, mortality
Brief summary
The aim of the study is to measure the effectiveness of a pilot program in Guangxi, China to decrease mortality related to HIV. The study's proposed mechanism of decreasing mortality rates is to shorten the time between initial HIV screening and ART implementation to within two weeks. The study population consists of participants who received an initial HIV infection diagnosis within the study period. Medical institutions will provide one-stop services by following detailed guidelines regarding reporting of positive HIV antibody screenings, further testing procedures, and treatment referrals in accordance with a pre-determined timetable. In addition, additional strategies focusing on policy development, medical personnel training, and a broad general public education campaign will be implemented. Main assessment measures are HIV-related mortality rates, treatment coverage, or other health outcomes.
Detailed description
The aim of the study is to measure the effectiveness of a pilot program in Guangxi, China to decrease mortality related to HIV/AIDS. In past years, Guangxi has experienced a relatively high rate of late HIV diagnoses, which has contributed to a significant proportion of HIV-related deaths occurring in the same year of initial diagnosis. The study's proposed mechanism of decreasing mortality rates is to shorten the time between initial HIV screening and ART implementation to within two weeks. Two pilot sites were selected based on past core assessment indicators. The study population consists of participants who received an initial HIV infection diagnosis within the study period. Medical institutions will provide one-stop services by following detailed guidelines regarding reporting of positive HIV antibody screenings, further testing procedures, and treatment referrals in accordance with a pre-determined timetable. In addition, additional strategies focusing on policy development, medical personnel training, and a broad general public education campaign will be implemented. The study will be performed from July,2012 to July,2015. Main assessment measures are HIV-related mortality rates, treatment coverage, or other health outcomes. 1. HIV-related mortality rates of participants who are newly diagnosed during the study period Numerator: Number of all-cause deaths during the study period Denominator: Number of HIV infected patients followed during the study period. 2. Percentage of newly diagnosed HIV-infected participants who receive ART Numerator: Number of patients who are diagnosed with HIV and initiate ART during the study period Denominator: Number of newly reported HIV cases during the study period
Interventions
BEHAVIORALImmediate post-screening treatment education
immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
Sponsors
Guangxi Center for Disease Control and Prevention
AbbVie
National Center for AIDS/STD Control and Prevention, China CDC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* New diagnosis of HIV infection as defined by having positive HIV antibody screening results between July 1, 2012 and July 1, 2015 OR * Having a current residential address inside of pilot site limits
Exclusion criteria
* Current residing outside of the borders of the designated study sites
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mortality | 12 months | HIV-related mortality rates of participants who are newly diagnosed during the study period Numerator: Number of all-cause deaths during the study period Denominator: Number of HIV infected patients followed during the study period. |
| ART treatment coverage | 12 months | Percentage of newly diagnosed HIV-infected participants who receive ART Numerator: Number of patients who are diagnosed with HIV and initiate ART during the study period Denominator: Number of newly reported HIV cases during the study period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mortality | 36 months | mortality rates of participants who are newly diagnosed during the study period Numerator: Number of all-cause deaths during the study period Denominator: Number of HIV infected patients followed during the study period. |
| ART treatment coverage | 36 months | Percentage of newly diagnosed HIV-infected participants who receive ART Numerator: Number of patients who are diagnosed with HIV and initiate ART during the study period Denominator: Number of newly reported HIV cases during the study period |
Countries
China
Contacts
Primary ContactZunyou Wu, PhD
Outcome results
None listed